Stay updated with breaking news from Robert Barrow. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Earlier this week, biopharma company Mind Medicine (MindMed) (NASDAQ: MNMD) released latest clinical trial results on repeated sub-perceptual doses of its LSD compound, MM-120, in adults with ADHD. The company also provided a corporate update and outlook for 2024.
Baird R W upgraded shares of Mind Medicine (MindMed) (NASDAQ:MNMD – Free Report) to a strong-buy rating in a research report released on Wednesday morning, Zacks.com reports. Several other equities research analysts have also commented on MNMD. SVB Leerink started coverage on shares of Mind Medicine (MindMed) in a research note on Monday, April 15th. […]
-inc-logo.png&w=240&h=240&zc=2){kind=logo}
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) CEO Robert Barrow sold 13,237 shares of the company’s stock in a transaction on Tuesday, December 26th. The shares were sold at an average price of $3.63, for a total transaction of $48,050.31. Following the transaction, the chief executive officer now owns 596,721 shares of the […]
A lead candidate psychedelic drug developed by the US company MindMed has shown the potential to treat generalized anxiety disorder in a phase 2b trial.
Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) have been given an average rating of “Buy” by the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have covered the […]